I got my 7th Spinraza injection and it was quite a long day!
Spinraza (nusinersen) is a prescription drug used to treat spinal muscular atrophy. Spinraza can cause side effects that range from mild to serious. Examples include headache and fever.
Earnings included compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 43 cents against a gain of 12 cents per share in the year-ago quarter.
Hosted on MSN7d
Hannah Ditched Shane.
In this episode, we reflect upon recent events, including our delicious Thanksgiving, Shane’s latest Spinraza injection, ...
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
The cuts in funding to Cold Spring Harbor Laboratory are one of many being proposed to science and research centers across ...
Ionis Pharmaceuticals (NASDAQ:IONS) stock gains as company reports strong Q4 results fueled by new product rollouts like ...
Ionis is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...
William Blair issued their Q1 2026 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report released on Wednesday, February 19th. William Blair analyst M. Minter forecasts that the ...
During Q4, Ionis reported revenues of $227 million, 68.1% above the $135 million estimated by analysts. That positive surprise was attributed in part to the successful launch and commercialization of ...